The goal of the Phase I part of this clinical research study is to find the highest tolerable
dose of Revlimid® (lenalidomide) that can be given in combination with paclitaxel to patients
with prostate cancer who have failed treatment with taxanes.
The goal of the Phase II part of this clinical research study is to learn if lenalidomide and
paclitaxel can help to control prostate cancer.
The safety of this combination treatment will be studied in both phases of the study.
UPDATE:
Study was terminated early due to slow accrual as a Phase I dose escalation study, without
progression to Phase II study portion.